Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2022 Nov 14;113(3):660–669. doi: 10.1002/cpt.2768

Table 3.

Summary of TTE model parameters for risk of recurrence by treatment arm or by K76T genotypes

Estimate 95% CI
Model: Risk of recurrence by treatment arm
θ 1 Mean of log-normal hazard distribution 0.683 0.566, 0.799
θ 2 SD of log-normal hazard distribution 3.96 3.81, 4.10
 θ3 HIV on hazard function −0.514 −0.666, −0.363
 θ4 C50 lumefantrine concentration (ng/mL) on hazard function 182 29.8, 335
Model: Risk of recurrence with different K76T genotypes
 θ1 Mean of log-normal hazard distribution 0.428 0.312, 0.544
 θ2 SD of log-normal hazard distribution 3.45 3.34, 3.55
 θ3 C50 lumefantrine concentration (ng/mL) on hazard function 128 20.4, 235
 θ4 K76T mutation on C50 0.284 −0.0692, 0.637

CI, confidence intervals; C50, concentration of lumefantrine that reduced the risk of recurrence by half on a log-scale; TTE, time-to-event.

Confidence intervals = estimate ± 1.96 * SE.

For both time to event models, theta 1 and 2 were structural model parameters and theta 3 and 4 were covariate effects.